Regeneron Pharmaceuticals delivered a robust third-quarter performance, comfortably surpassing analyst estimates thanks to booming sales of its star drug Dupixent and solid contributions from Libtayo. Yet, the jubilant headlines mask underlying complexities: Eylea, a long-standing revenue driver, faces escalating competition and critical regulatory delays for its high-dose successor, Eylea HD, setting the stage for a pivotal period for the biotech giant.
On Tuesday, October 28, 2025, Regeneron Pharmaceuticals (NASDAQ: REGN) sent a ripple of optimism through the market, with its shares climbing 5.6% premarket after announcing third-quarter results that decisively beat Wall Street expectations. The impressive performance was primarily propelled by the continued surging demand for its eczema treatment, Dupixent, and strong sales of its cancer therapy, Libtayo. While the immediate reaction was positive, a closer look reveals a mixed picture, particularly concerning the company’s crucial eye disease franchise, Eylea, which is grappling with significant competitive pressures and regulatory setbacks.
Dupixent Leads the Charge: A Partnership Powerhouse
The undisputed highlight of Regeneron’s quarter was Dupixent. Analysts have consistently praised the drug’s performance, which once again topped quarterly sales expectations. Developed in partnership with French pharmaceutical giant Sanofi, Dupixent’s success underscores the power of strategic alliances in the complex drug development landscape. Its robust demand for eczema treatment has made it a foundational pillar of Regeneron’s revenue growth and a strong counterbalance to challenges faced by other segments of its portfolio. This consistent outperformance is a testament to its market penetration and the unmet needs it addresses in its therapeutic areas. Investors closely track its sales, which are a strong indicator of the company’s current financial health and future growth potential, as highlighted by a recent Reuters report Reuters.
For more insights into the performance of this critical partnership and Sanofi’s broader portfolio, shareholders often refer to their official investor relations publications, which detail contribution margins and market strategies for key products like Dupixent. Such details provide a deeper understanding of the collaborative successes driving Regeneron’s top line Sanofi Investor Relations.
Eylea Under Pressure: Competition and Regulatory Roadblocks
In stark contrast to Dupixent’s stellar trajectory, Regeneron’s long-standing blockbuster eye disease drug, Eylea, is navigating a turbulent period. The drug is facing increasingly stiff competition from cheaper biosimilar versions and formidable rivals, most notably Roche’s Vabysmo. Last week, Roche reported that third-quarter sales for Vabysmo, a treatment for a common form of blindness in the elderly, reached 996 million Swiss francs ($1.26 billion). This figure, however, missed expectations for the second consecutive quarter, indicating a highly competitive and dynamic market for ophthalmic treatments.
To mitigate these challenges, Regeneron is actively working to transition its customer base to a newer formulation: Eylea HD. This high-dosage version is designed to allow longer intervals between injections for patients, potentially enhancing convenience and improving adherence. However, the path to market for Eylea HD has hit a significant snag. On Monday, the U.S. Food and Drug Administration (FDA) declined to approve the pre-filled syringe version of Eylea HD. The agency cited unresolved inspection findings at the Catalent facility in Bloomington, Indiana, as the reason for the setback.
This regulatory hurdle is not an isolated incident for Regeneron, as the company is reportedly facing multiple regulatory issues linked to problems at the Catalent facility. This specific facility gained further attention in late 2024 when it was acquired by pharmaceutical giant Novo Nordisk. The delay is significant for Regeneron’s strategic plans for Eylea. According to Raymond James analysts, Regeneron aims to submit a new filler application for Eylea HD by January 2026, with potential FDA approval estimated by April or May of the same year.
Analysts largely view the existing Eylea franchise as stable, providing a steady revenue stream. However, they do not anticipate significant growth until Regeneron secures key label and format extensions for Eylea HD, which now appear likely to be delayed into 2026. This extended timeline underscores the importance of the regulatory resolution for the Catalent facility and the successful approval of Eylea HD to maintain the company’s competitive edge in the ophthalmology market.
Libtayo’s Steady Contribution
Beyond the high-stakes dynamics of Dupixent and Eylea, Regeneron’s skin cancer treatment, Libtayo, quietly delivered a strong quarter. The drug generated sales of $365 million, comfortably exceeding analyst estimates of $343.75 million. This consistent performance demonstrates the diversified strength of Regeneron’s product portfolio and its ability to generate significant revenue from multiple therapeutic areas, cushioning some of the impact from the Eylea franchise’s challenges.
The Numbers Speak: Regeneron’s Financial Snapshot
Overall, Regeneron’s financial performance for the third quarter of 2025 painted a picture of strong execution against analyst expectations:
- Total Revenue: The company reported total revenue of $3.75 billion, surpassing the average analyst estimate of $3.59 billion, according to data compiled by LSEG.
- High-Dose Eylea Sales: U.S. sales of the 8-milligram high-dose version of Eylea, developed in collaboration with Bayer AG, increased by 10% from a year ago, reaching $431 million. This growth in the high-dose formulation shows early signs of successful transition efforts, even amidst broader franchise challenges.
- Adjusted Quarterly Profit: Regeneron earned an adjusted quarterly profit of $11.83 per share, significantly outperforming expectations of $9.59 per share. This strong profit margin highlights efficient operations and effective cost management.
Investor Outlook: Navigating Growth and Challenges
For investors focused on the long-term, Regeneron’s Q3 earnings present a compelling narrative of a company with powerful growth drivers and significant strategic challenges. The continued strength of Dupixent provides a robust foundation, making it a critical asset in the company’s portfolio. Its performance offsets some of the competitive and regulatory headwinds facing Eylea.
The regulatory delays for Eylea HD, stemming from the Catalent facility issues, require careful monitoring. While analysts view the current Eylea franchise as stable, sustained growth hinges on the successful approval and market adoption of Eylea HD. The anticipated approval timeline in 2026 will be a key factor for the stock’s trajectory. Investors will need to weigh the consistent outperformance of Dupixent and Libtayo against the uncertainties surrounding Eylea’s future growth and the broader competitive landscape in ophthalmology.
In conclusion, Regeneron’s third quarter showcased its ability to exceed financial targets, driven by its leading immunology and oncology assets. However, the investment narrative is becoming increasingly nuanced, with the evolving situation around its critical eye care franchise demanding continued strategic focus and careful investor scrutiny.
